Digirad Corporation (Nasdaq:DRAD) today reported its financial
results for the third quarter and nine months ended September 30,
2016.
Total revenues for the 2016 third quarter were
$31.1 million, an increase of 96 percent compared to the prior
year’s third quarter revenues of $15.9 million.
Net loss for the 2016 third quarter was $0.3
million, or $0.01 net loss per diluted share, compared to net
income of $19.1 million, or $0.97 per diluted share from the same
period in the prior year. Adjusted net income for the 2016 third
quarter was $1.0 million, or $0.05 per diluted share, compared to
$1.5 million, or $0.08 per diluted share from the same period in
the prior year.
Adjusted EBITDA for the 2016 third quarter was
$3.6 million, compared to $2.2 million in the prior year third
quarter.
Total revenues for the nine months ended
September 30, 2016 were $94.3 million, an increase of 109 percent
compared to the prior year’s revenues for the first nine months of
$45.2 million.
Net income for the nine months ended September
30, 2016 was $12.3 million, or $0.62 per diluted share, compared to
net income of $21.0 million, or $1.07 per diluted share in the same
period in the prior year. Adjusted net income for the nine months
ended September 30, 2016 was $4.4 million, or $0.22 per diluted
share, compared to adjusted net income of $3.2 million, or $0.16
per diluted share in the same period in the prior year.
Adjusted EBITDA for the nine months ended
September 30, 2016 was $11.4 million, compared to $5.0 million in
the same period in the prior year. A reconciliation of adjusted net
income and adjusted EBITDA is provided later in this release.
The results for the third quarter and nine
months ended September 30, 2016 include the results of the recent
acquisition of DMS Health, which closed on January 1, 2016.
Digirad President and CEO Matt Molchan said, “We
are pleased with our results this quarter, and the performance of
all our businesses, including the business units of DMS Health that
we acquired at the beginning of the year. As we have stated before,
our results can be affected by the timing of product sales on a
quarter by quarter basis, and during the third quarter we did
experience some of this timing as well as higher than normal parts
cost for our product service businesses. However, we expect the
product sales timing and underlying parts cost to balance out by
the end of the year and continue to be confident of our full year
financial guidance, which is supported by our significant year over
year performance on a year to date basis through September
2016.”
Digirad Chief Financial Officer Jeff Keyes said,
“We are also pleased with the momentum of our cash flow generation
on a year to date basis, which beyond our normal quarterly
dividend, allowed us to make three extra payments on the highest
interest rate tranche of our credit facility. Paying down debt not
only reduces our interest expense but it also accretes additional
value to our shareholders. And finally, we are excited that we are
nearly complete with our operational integration of DMS Health, and
expect to finish all major planned integration activities by year
end."
The Company also announced a cash dividend of $0.05 cents per
share that will be paid on November 28, 2016, to shareholders of
record on November 17, 2016.
2016 Financial Guidance
The Company reaffirms its previously announced
fiscal year 2016 financial guidance of revenues between $125
million and $130 million, non-GAAP adjusted EBITDA between $17
million and $18 million, and adjusted diluted earnings per share of
between $0.30 and $0.35.
Conference Call Information
A conference call is scheduled for 10:00 a.m. EDT on October 28,
2016 to discuss the results and management's outlook. The call may
be accessed by dialing 1-877-407-9039 (international callers:
+1-201-689-8470) five minutes prior to the scheduled start time and
referencing Digirad. A simultaneous webcast of the call may be
accessed online from the Events & Presentations link on the
Investor Relations page at http://drad.client.shareholder.com; an
archived replay of the webcast will be available within 15 minutes
of the end of the conference call.
Use of Non-GAAP Financial Measures by
Digirad Corporation
This Digirad news release presents the non-GAAP financial
measures “adjusted net income,” “adjusted net income per diluted
share,” and “adjusted EBITDA.” The most directly comparable measure
for these non-GAAP financial measures are net income and diluted
net income per share. The Company has included below unaudited
adjusted financial information, which presents the Company's
results of operations after excluding acquired intangible asset
amortization, acquisition related contingent consideration
adjustments, investment impairment loss, transaction and
integration costs associated with DMS Health Technologies, and
non-recurring related income tax adjustments. Further
excluded in the measure of adjusted EBITDA are interest, taxes,
depreciation, amortization and stock-based compensation.
A discussion of the reasons why management believes that the
presentation of non-GAAP financial measures provides useful
information to investors regarding Digirad's financial condition
and results of operations is included as Exhibit 99.2 to Digirad's
report on Form 8-K filed with the Securities and Exchange
Commission on October 28, 2016.
About Digirad Corporation
Digirad delivers convenient, effective, and efficient healthcare
solutions on an as needed, when needed, and where needed
basis. Digirad’s diverse portfolio of mobile healthcare
solutions and medical equipment and services, including diagnostic
imaging and patient monitoring, provides hospitals, physician
practices, and imaging centers through the United States access to
technology and services necessary to provide exceptional patient
care in the rapidly changing healthcare environment. For more
information, please visit www.digirad.com.
Forward-Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995. Some of these forward-looking statements can be
identified by the use of forward-looking words such as “believes,”
“expects,” “may,” “will,” “should,” “seek,” “approximately,”
“intends,” “plans,” “estimates,” or “anticipates,” or the negative
of those words or other comparable terminology, or in specific
statements such as the Company's ability to deliver value to
customers, the ability to grow and generate positive cash flow, the
ability to execute on restructuring activities, and ability to
successfully execute acquisitions. These forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from the statements made. These risks
are detailed in Digirad's filings with the U.S. Securities and
Exchange Commission, including the Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other reports. Readers are cautioned to not place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Digirad undertakes no
obligation to revise or update the forward-looking statements
contained herein.
(Financial tables follow)
Digirad
Corporation Condensed Consolidated Statements
of Income (Loss)(Unaudited)
|
Three Months Ended |
|
Nine Months Ended |
|
September 30, |
|
September 30, |
(in thousands,
except per share amounts) |
2016 |
|
2015 |
|
2016 |
|
2015 |
|
|
|
|
|
|
|
|
Revenues: |
|
|
|
|
|
|
|
Services |
$ |
23,825 |
|
|
$ |
11,982 |
|
|
$ |
72,496 |
|
|
$ |
34,724 |
|
Product and product-related |
7,261 |
|
|
3,880 |
|
|
21,837 |
|
|
10,525 |
|
Total revenues |
31,086 |
|
|
15,862 |
|
|
94,333 |
|
|
45,249 |
|
Cost of revenues: |
|
|
|
|
|
|
|
Services |
19,110 |
|
|
9,201 |
|
|
56,795 |
|
|
26,920 |
|
Product and product-related |
3,675 |
|
|
1,859 |
|
|
10,407 |
|
|
5,112 |
|
Total cost of revenues |
22,785 |
|
|
11,060 |
|
|
67,202 |
|
|
32,032 |
|
|
|
|
|
|
|
|
|
Gross profit |
8,301 |
|
|
4,802 |
|
|
27,131 |
|
|
13,217 |
|
Total gross profit
percentage |
26.7 |
% |
|
30.3 |
% |
|
28.8 |
% |
|
29.2 |
% |
Services gross profit
percentage |
19.8 |
% |
|
23.2 |
% |
|
21.7 |
% |
|
22.5 |
% |
Product and product-related
gross profit percentage |
49.4 |
% |
|
52.1 |
% |
|
52.3 |
% |
|
51.4 |
% |
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
Marketing and sales |
2,426 |
|
|
1,212 |
|
|
7,888 |
|
|
3,689 |
|
General and administrative |
4,608 |
|
|
2,508 |
|
|
15,900 |
|
|
6,880 |
|
Amortization of intangible
assets |
578 |
|
|
134 |
|
|
1,735 |
|
|
372 |
|
Total operating expenses |
7,612 |
|
|
3,854 |
|
|
25,523 |
|
|
10,941 |
|
|
|
|
|
|
|
|
|
Income from
operations |
689 |
|
|
948 |
|
|
1,608 |
|
|
2,276 |
|
|
|
|
|
|
|
|
|
Other expense: |
|
|
|
|
|
|
|
Other expense, net |
(428 |
) |
|
— |
|
|
(414 |
) |
|
— |
|
Interest expense, net |
(342 |
) |
|
(11 |
) |
|
(1,092 |
) |
|
(12 |
) |
Total other
expense |
(770 |
) |
|
(11 |
) |
|
(1,506 |
) |
|
(12 |
) |
|
|
|
|
|
|
|
|
(Loss) income before
income taxes |
(81 |
) |
|
937 |
|
|
102 |
|
|
2,264 |
|
Income tax (expense)
benefit |
(202 |
) |
|
18,183 |
|
|
12,222 |
|
|
18,698 |
|
Net (loss) income |
$ |
(283 |
) |
|
$ |
19,120 |
|
|
$ |
12,324 |
|
|
$ |
20,962 |
|
|
|
|
|
|
|
|
|
Net (loss) income per
share: |
|
|
|
|
|
|
|
Basic |
$ |
(0.01 |
) |
|
$ |
0.99 |
|
|
$ |
0.63 |
|
|
$ |
1.09 |
|
Diluted |
$ |
(0.01 |
) |
|
$ |
0.97 |
|
|
$ |
0.62 |
|
|
$ |
1.07 |
|
Dividends declared per
common share |
$ |
0.05 |
|
|
$ |
0.05 |
|
|
$ |
0.15 |
|
|
$ |
0.15 |
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding – basic |
19,618 |
|
|
19,356 |
|
|
19,532 |
|
|
19,145 |
|
Weighted average shares
outstanding – diluted |
19,618 |
|
|
19,798 |
|
|
20,026 |
|
|
19,608 |
|
|
|
|
|
|
|
|
|
Digirad
Corporation Condensed Consolidated Balance
Sheets(Unaudited)
(in
thousands) |
September 30, 2016 |
|
December 31, 2015 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
2,353 |
|
|
$ |
15,868 |
|
Securities available-for-sale |
1,313 |
|
|
3,227 |
|
Accounts receivable, net |
13,637 |
|
|
7,274 |
|
Inventories, net |
5,909 |
|
|
4,381 |
|
Restricted cash |
233 |
|
|
233 |
|
Other current assets |
3,649 |
|
|
764 |
|
Total current assets |
27,094 |
|
|
31,747 |
|
Property and equipment,
net |
31,119 |
|
|
6,252 |
|
Intangible assets,
net |
12,206 |
|
|
3,079 |
|
Goodwill |
6,819 |
|
|
2,897 |
|
Deferred tax assets |
26,100 |
|
|
18,578 |
|
Restricted cash |
2,845 |
|
|
— |
|
Other assets |
903 |
|
|
1,560 |
|
Total assets |
$ |
107,086 |
|
|
$ |
64,113 |
|
|
|
|
|
Liabilities and
stockholders’ equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
6,466 |
|
|
$ |
1,369 |
|
Accrued compensation |
4,232 |
|
|
2,453 |
|
Accrued warranty |
153 |
|
|
213 |
|
Deferred revenue |
3,317 |
|
|
1,673 |
|
Current portion of long-term
debt |
5,358 |
|
|
— |
|
Other current liabilities |
4,237 |
|
|
2,998 |
|
Total current liabilities |
23,763 |
|
|
8,706 |
|
Long-term debt, net of
current portion |
17,340 |
|
|
— |
|
Other liabilities |
1,163 |
|
|
1,252 |
|
Total liabilities |
42,266 |
|
|
9,958 |
|
|
|
|
|
Stockholders’ equity: |
|
|
|
Preferred stock |
— |
|
|
— |
|
Common stock |
2 |
|
|
2 |
|
Treasury stock |
(5,728 |
) |
|
(5,728 |
) |
Additional paid-in capital |
151,961 |
|
|
153,860 |
|
Accumulated other comprehensive
loss |
— |
|
|
(240 |
) |
Accumulated deficit |
(81,415 |
) |
|
(93,739 |
) |
Total stockholders’ equity |
64,820 |
|
|
54,155 |
|
Total liabilities and stockholders’
equity |
$ |
107,086 |
|
|
$ |
64,113 |
|
|
|
|
|
|
|
|
|
Digirad
CorporationReconciliation of Non-GAAP Financial
Measures(Unaudited)
|
|
|
Three Months Ended September
30, |
|
Nine Months Ended September 30, |
(in
thousands, except per share amounts) |
|
2016 |
|
2015 |
|
2016 |
|
2015 |
|
|
|
|
|
|
|
|
|
|
Net
(loss) income |
|
$ |
(283 |
) |
|
$ |
19,120 |
|
|
$ |
12,324 |
|
|
$ |
20,962 |
|
|
Acquired intangible
amortization |
|
578 |
|
|
131 |
|
|
1,735 |
|
|
365 |
|
|
Acquisition related
contingent consideration valuation adjustment(1) |
|
(5 |
) |
|
— |
|
|
(8 |
) |
|
(173 |
) |
|
Investment impairment
loss(2) |
|
414 |
|
|
— |
|
|
414 |
|
|
— |
|
|
Transaction and
integration costs of DMS Health Technologies(3) |
|
127 |
|
|
435 |
|
|
1,748 |
|
|
743 |
|
|
Income tax
items(4) |
|
170 |
|
|
(18,163 |
) |
|
(11,860 |
) |
|
(18,699 |
) |
Non-GAAP Adjusted net income |
|
$ |
1,001 |
|
|
$ |
1,523 |
|
|
$ |
4,353 |
|
|
$ |
3,198 |
|
|
|
|
|
|
|
|
|
|
|
Net
(loss) income per share - diluted(5) |
|
$ |
(0.01 |
) |
|
$ |
0.97 |
|
|
$ |
0.62 |
|
|
$ |
1.07 |
|
|
Acquired intangible
amortization |
|
0.03 |
|
|
0.01 |
|
|
0.09 |
|
|
0.02 |
|
|
Acquisition related
contingent consideration valuation adjustment(1) |
|
— |
|
|
— |
|
|
— |
|
|
(0.01 |
) |
|
Investment impairment
loss(2) |
|
0.02 |
|
|
— |
|
|
0.02 |
|
|
— |
|
|
Transaction and
integration costs of DMS Health Technologies(3) |
|
0.01 |
|
|
0.02 |
|
|
0.09 |
|
|
0.04 |
|
|
Income tax
items(4) |
|
0.01 |
|
|
(0.92 |
) |
|
(0.59 |
) |
|
(0.95 |
) |
Non-GAAP Adjusted net income per share -
diluted(5) |
|
$ |
0.05 |
|
|
$ |
0.08 |
|
|
$ |
0.22 |
|
|
$ |
0.16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September
30, |
|
Nine Months Ended September 30, |
(in
thousands) |
|
2016 |
|
2015 |
|
2016 |
|
2015 |
|
|
|
|
|
|
|
|
|
|
Net
(loss) income |
|
$ |
(283 |
) |
|
$ |
19,120 |
|
|
$ |
12,324 |
|
|
$ |
20,962 |
|
|
Acquisition related
contingent consideration valuation adjustment(1) |
|
(5 |
) |
|
— |
|
|
(8 |
) |
|
(173 |
) |
|
Investment impairment
loss(2) |
|
414 |
|
|
— |
|
|
414 |
|
|
— |
|
|
Transaction and
integration costs of DMS Health Technologies(3) |
|
127 |
|
|
435 |
|
|
1,748 |
|
|
743 |
|
|
Depreciation and
amortization |
|
2,489 |
|
|
665 |
|
|
7,337 |
|
|
1,751 |
|
|
Stock-based
compensation |
|
274 |
|
|
165 |
|
|
754 |
|
|
450 |
|
|
Interest income |
|
(3 |
) |
|
(10 |
) |
|
(12 |
) |
|
(32 |
) |
|
Interest expense |
|
345 |
|
|
21 |
|
|
1,104 |
|
|
44 |
|
|
Income tax expense
(benefit) |
|
202 |
|
|
(18,183 |
) |
|
(12,222 |
) |
|
(18,698 |
) |
Non-GAAP Adjusted EBITDA |
|
$ |
3,560 |
|
|
$ |
2,213 |
|
|
$ |
11,439 |
|
|
$ |
5,047 |
|
|
|
|
|
|
|
|
|
|
|
(1) Reflects fair value adjustment to
estimate of contingent consideration related to
acquisitions.(2) Reflects impairment losses related to
investment in Perma-Fix Medical. Amount consists of a
write-down of the investment to its fair market value that was
considered other than temporary.(3) Reflects diligence,
transaction, and integration costs related to the acquisition of
DMS Health Technologies.(4) Reflects income tax effect for
adjusted financial data and acquisition related income tax
adjustments, and release of previously reserved net operating loss
carryforwards.(5) Per share amounts are computed independently
for each discrete item presented. Therefore, the sum of the
quarterly per share amounts will not necessarily equal to the total
for the year, and sum of individual items may not equal the
total.
Digirad
CorporationReconciliation of Non-GAAP Financial
Measures(Unaudited)
|
|
|
Three Months Ended |
(in
thousands, except per share amounts) |
|
September 30, 2015 |
|
December 31, 2015 |
|
March 31, 2016 |
|
June 30, 2016 |
|
September 30, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss) |
|
$ |
19,120 |
|
|
$ |
678 |
|
|
$ |
11,609 |
|
|
$ |
998 |
|
|
$ |
(283 |
) |
|
Acquired intangible
amortization |
|
131 |
|
|
131 |
|
|
577 |
|
|
578 |
|
|
578 |
|
|
Acquisition related
contingent consideration valuation adjustment(1) |
|
— |
|
|
113 |
|
|
— |
|
|
(3 |
) |
|
(5 |
) |
|
Investment impairment
loss(2) |
|
— |
|
|
278 |
|
|
— |
|
|
— |
|
|
414 |
|
|
Transaction and
integration costs of DMS Health Technologies(3) |
|
435 |
|
|
595 |
|
|
1,450 |
|
|
171 |
|
|
127 |
|
|
Income tax
items(4) |
|
(18,163 |
) |
|
(446 |
) |
|
(12,333 |
) |
|
67 |
|
|
170 |
|
Non-GAAP Adjusted net income |
|
$ |
1,523 |
|
|
$ |
1,349 |
|
|
$ |
1,303 |
|
|
$ |
1,811 |
|
|
$ |
1,001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss) per share - diluted(5) |
|
$ |
0.97 |
|
|
$ |
0.03 |
|
|
$ |
0.58 |
|
|
$ |
0.05 |
|
|
$ |
(0.01 |
) |
|
Acquired intangible
amortization |
|
0.01 |
|
|
0.01 |
|
|
0.03 |
|
|
0.03 |
|
|
0.03 |
|
|
Acquisition related
contingent consideration valuation adjustment(1) |
|
— |
|
|
0.01 |
|
|
— |
|
|
— |
|
|
— |
|
|
Investment impairment
loss(2) |
|
— |
|
|
0.01 |
|
|
— |
|
|
— |
|
|
0.02 |
|
|
Transaction and
integration costs of DMS Health Technologies(3) |
|
0.02 |
|
|
0.03 |
|
|
0.07 |
|
|
0.01 |
|
|
0.01 |
|
|
Income tax
items(4) |
|
(0.92 |
) |
|
(0.02 |
) |
|
(0.62 |
) |
|
— |
|
|
0.01 |
|
Non-GAAP Adjusted net income per share -
diluted(5) |
|
$ |
0.08 |
|
|
$ |
0.07 |
|
|
$ |
0.07 |
|
|
$ |
0.09 |
|
|
$ |
0.05 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
(in
thousands) |
|
September 30, 2015 |
|
December 31, 2015 |
|
March 31, 2016 |
|
June 30, 2016 |
|
September 30, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss) |
|
$ |
19,120 |
|
|
$ |
678 |
|
|
$ |
11,609 |
|
|
$ |
998 |
|
|
$ |
(283 |
) |
|
Acquisition related
contingent consideration valuation adjustment(1) |
|
— |
|
|
113 |
|
|
— |
|
|
(3 |
) |
|
(5 |
) |
|
Investment impairment
loss(2) |
|
— |
|
|
278 |
|
|
— |
|
|
— |
|
|
414 |
|
|
Transaction and
integration costs of DMS Health Technologies(3) |
|
435 |
|
|
595 |
|
|
1,450 |
|
|
171 |
|
|
127 |
|
|
Depreciation and
amortization |
|
665 |
|
|
690 |
|
|
2,465 |
|
|
2,383 |
|
|
2,489 |
|
|
Stock-based
compensation |
|
165 |
|
|
166 |
|
|
223 |
|
|
257 |
|
|
274 |
|
|
Interest income |
|
(10 |
) |
|
(7 |
) |
|
(5 |
) |
|
(4 |
) |
|
(3 |
) |
|
Interest expense |
|
21 |
|
|
19 |
|
|
375 |
|
|
383 |
|
|
345 |
|
|
Income tax expense
(benefit) |
|
(18,183 |
) |
|
(425 |
) |
|
(12,461 |
) |
|
37 |
|
|
202 |
|
Non-GAAP Adjusted EBITDA |
|
$ |
2,213 |
|
|
$ |
2,107 |
|
|
$ |
3,656 |
|
|
$ |
4,222 |
|
|
$ |
3,560 |
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Reflects fair value adjustment to
estimate of contingent consideration related to
acquisitions.(2) Reflects impairment losses related to
investment in Perma-Fix Medical. Amounts consist of
impairment of a Supply Agreement entered into between the two
parties, a loss related to the initial excess of the transaction
price over fair value and a write-down of the investment to its
fair market value that was considered other than
temporary.(3) Reflects diligence, transaction, and integration
costs related to the acquisition of DMS Health
Technologies.(4) Reflects income tax effect for adjusted
financial data and acquisition related income tax adjustments, and
release of previously reserved net operating loss
carryforwards.(5) Per share amounts are computed independently
for each discrete item presented. Therefore, the sum of the
quarterly per share amounts will not necessarily equal to the total
for the year, and sum of individual items may not equal the
total.
For more information contact:
Jeff Keyes
Chief Financial Officer
858-726-1600
ir@digirad.com
Digirad (NASDAQ:DRAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Digirad (NASDAQ:DRAD)
Historical Stock Chart
From Apr 2023 to Apr 2024